???global.info.a_carregar???
Ana Filipa Fernandes da Cruz has a Master degree in Pharmaceutical Sciences (University of Coimbra) and currently she is enrolled in the PhD program in Pharmaceutical Sciences, specialization in Pharmaceutical Technology, at the Center for Neuroscience and Cell Biology (University of Coimbra). Throughout the PhD, she obtained the experience at molecular and cellular level that includes, cell culture (cancer cell lines of diverse histological origin and cancer stem cells), cytotoxicity assays (resazurin reduction assay and LIVE/DEAD cell viability assay), Western Blotting, Flow Cytometry, quantitative RT-PCR and cellular migration. Moreover, Ana Cruz has experience in liposome production (functionalized and/or fluorescent and/or loaded with drugs). Also, she has a significant level of autonomy, at the various levels of the scientific activity and know to carefully plan the experiments. Ana Cruz has already several poster presentations, scientific peer-reviewed papers and oral communications in her curriculum vitae.
Ler resumo completo ↓
Identificação

Identificação pessoal

Nome completo
Ana Filipa Fernandes da Cruz

Nomes de citação

  • Cruz, Ana F

Identificadores de autor

Ciência ID
321D-3A30-6F31
ORCID iD
0000-0002-3404-5755

Endereços de correio eletrónico

  • ana.filipa.cruz@cnc.uc.pt (Profissional)

Moradas

  • Vectors and Gene Therapy Lab, Center for Neuroscience and Cell Biology (CNC). Rua Larga, Faculdade de Medicina, Pólo I, 2º andar, 3004-504, Coimbra, Coimbra, Portugal (Profissional)

Domínios de atuação

  • Ciências Naturais - Ciências Biológicas

Idiomas

Idioma Conversação Leitura Escrita Compreensão Peer-review
Inglês Utilizador independente (B1) Utilizador independente (B1) Utilizador independente (B1) Utilizador independente (B1)
Formação
Grau Classificação
2013/02/01 - 2022/07/28
Concluído
 Doutoramento em Ciências Farmacêuticas (Doutoramento)
Universidade de Coimbra Faculdade de Farmácia, Portugal

Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
2014/01/23
Concluído
 Curso de Ciências de Animais de Laboratório, categoria B* (Outros)
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
2012
Concluído
 Mestrado Integrado em Ciências Farmacêuticas (Mestrado)
Universidade de Coimbra Faculdade de Farmácia, Portugal
"n/a" (TESE/DISSERTAÇÃO)
 17 valores
Percurso profissional

Ciência

Categoria Profissional
Instituição de acolhimento 		Empregador
2013/02/01 - Atual Investigador (Investigação) Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal

Outros

Categoria Profissional
Instituição de acolhimento 		Empregador
2013/02/01 - Atual PhD student Universidade de Coimbra Faculdade de Farmácia, Portugal
Projetos

Bolsa

Designação Financiadores
2017 - Atual HealthyAging 2020
CENTRO-01-0145-FEDER-000012
Bolseiro de Investigação
CNC.IBILI, Portugal

Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
Em curso
2017/07/01 - 2021/03/31 CANCEL_STEM_Estaminalidade das células do cancro: um desafio e uma oportunidade para avançar no tratamento em Oncologia¿
SAICTPAC/0022/2015 (POCI-01-0145-FEDER-016390)
Bolseiro de Investigação
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
Em curso
2016 - 2020 Towards a single therapy against triple negative breast cancer and neuroblastoma by nucleolin-mediated multicellular targeting with a synergistic drug combination.
EN/Med/0005/2015
Bolseiro de Investigação
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
Concluído
2013/02/01 - 2017/01/31 Insights into the mechanisms of dual targeted-triggered release lipid-based nanoparticles.
SFRH/BD/85554/2012
Bolseiro de Doutoramento
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal

Universidade de Coimbra Faculdade de Farmácia, Portugal
Fundação para a Ciência e a Tecnologia
Concluído

Outro

Designação Financiadores
2020/04 - 2020/06 COVID-19 Lab @ CNC / ViraVector
NA
Bolseiro de Investigação
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
Em curso
Produções

Publicações

Artigo em revista
  1. Ângela Valério-Fernandes; Nuno A. Fonseca; Nélio Gonçalves; Ana F. Cruz; Marta I. Pereira; Ana C. Gregório; Vera Moura; et al. "Nucleolin Overexpression Predicts Patient Prognosis While Providing a Framework for Targeted Therapeutic Intervention in Lung Cancer". Cancers 14 9 (2022): 2217-2217. https://doi.org/10.3390/cancers14092217.
    10.3390/cancers14092217
  2. Cruz, Ana Filipa; Fonseca, Nuno A.; Malheiro, Ana Rita; B. Melo, Joana; Gaspar, Maria Manuela; Fernandes, Rui; Moura, Vera; Simões, Sérgio; Moreira, João Nuno. "Targeted liposomal doxorubicin/ceramides combinations: The importance to assess the nature of drug interaction beyond bulk tumor cells". European Journal of Pharmaceutics and Biopharmaceutics 172 (2022): 61-77. http://dx.doi.org/10.1016/j.ejpb.2022.01.006.
    10.1016/j.ejpb.2022.01.006
  3. Ana F. Cruz; Mariana B. Caleiras; Nuno A. Fonseca; Nélio Gonçalves; Vera M. Mendes; Susana F. Sampaio; Vera Moura; et al. "The Enhanced Efficacy of Intracellular Delivery of Doxorubicin/C6-Ceramide Combination Mediated by the F3 Peptide/Nucleolin System Is Supported by the Downregulation of the PI3K/Akt Pathway". Cancers 13 12 (2021): 3052-3052. https://doi.org/10.3390/cancers13123052.
    10.3390/cancers13123052
  4. Brignole, Chiara; Bensa, Veronica; Fonseca, Nuno A.; Del Zotto, Genny; Bruno, Silvia; Cruz, Ana F.; Malaguti, Fabiana; et al. "Cell surface Nucleolin represents a novel cellular target for neuroblastoma therapy". Journal of Experimental & Clinical Cancer Research 40 1 (2021): http://dx.doi.org/10.1186/s13046-021-01993-9.
    10.1186/s13046-021-01993-9
  5. Cruz, Ana Filipa; Fonseca, Nuno Andre; Moura, Vera; Simoes, Sergio; Moreira, Joao Nuno. "Targeting Cancer Stem Cells and Non-Stem Cancer Cells: The Potential of Lipid- Based Nanoparticles". Current Pharmaceutical Design 23 43 (2018): 6563-6572. http://dx.doi.org/10.2174/1381612823666171115105252.
    10.2174/1381612823666171115105252
  6. Fonseca, Nuno A.; Cruz, Ana Filipa; Moura, Vera; Simões, Sérgio; Moreira, João Nuno. "The cancer stem cell phenotype as a determinant factor of the heterotypic nature of breast tumors". Critical Reviews in Oncology/Hematology 113 (2017): 111-121. http://dx.doi.org/10.1016/j.critrevonc.2017.03.016.
    Publicado • 10.1016/j.critrevonc.2017.03.016
Capítulo de livro
  1. Cruz, Ana Filipa; Fonseca, Nuno A.; Gregório, Ana C.; Moura, Vera; Simões, Sérgio; Moreira, João Nuno. "Moving Liposome Technology from the Bench to the Oncological Patient: Towards Performance-by-Design". In Particles and Nanoparticles in Pharmaceutical Products, 171-211. Springer International Publishing, 2018.
    10.1007/978-3-319-94174-5_4
  2. Fonseca, Nuno A.; Lopes, Rui M.; Cruz, Ana F.; Gregório, Ana C.; Valério-Fernandes, Ângela; Moura, Vera; Simões, Sérgio; Moreira, João Nuno. "Lipid-Based Nanosystems for the Delivery of siRNA: Challenges and Trends". In Handbook of Nanomaterials for Cancer Theranostics, 495-515. Elsevier, 2018.
    10.1016/b978-0-12-813339-2.00016-5
  3. Lopes, R.M.; Fonseca, N.A.; Cruz, A.F.; Gregório, A.C.; Valério-Fernandes, Â.; Moura, V.; Simões, S.; Moreira, J.N.. "Advances on nucleic acid delivery with nonviral vectors". In Bioinspired Materials for Medical Applications, 403-426. Elsevier, 2017.
    10.1016/b978-0-08-100741-9.00014-0
Poster em conferência
  1. Cruz, Ana F; Fonseca, Nuno A; Moura, Vera; Simões, Sérgio; Moreira, JN. "P3.4: The potential of F3 peptide-targeted liposomes containing doxorubicin and C6-ceramide to imbalenced cancer stem cell niche in nucleolin-overexpressing cell lines". Trabalho apresentado em 3rd SPLC-CRS Young Scientists Virtual Meeting, 2021.
  2. Cruz, Ana Filipa; Gonçalves, Nélio; Moura, Vera; Simões, Sérgio; Moreira, João Nuno. "The potential of liposomal C6-ceramide/doxorubicin targeted to nucleolin to decrease triple-negative breast cancer stem cell population, relative to a standard of treatment.". Trabalho apresentado em 46th Controlled Release Society Annual Meeting & Exposition, 2019.
  3. Cruz, Ana F; Fonseca, Nuno A; Moura, Vera; Simões, Sérgio; Moreira, JN. "Cytotoxicity of targeted liposomal C6-ceramide and doxorubicin against nucleolin-overexpressing cancer cell lines is supported by the downregulation of the Akt pathway and is more effective than conventional drug combinations". Trabalho apresentado em XII Spanish-Portuguese Conference on Controlled Drug Delivery, 2018.
  4. Cruz, Ana F; Fonseca, Nuno A; Sampaio, Susana F; Moura, Vera; Almeida, Ramiro D.; Simões, Sérgio; Moreira, JN. "Unraveling the therapeutic potential of targeted synergistic drug combination against nucleolin-overexpressing ovarian cancer cell lines.". Trabalho apresentado em XI Spanish-Portuguese Conference on Controlled Drug Delivery, 2016.
  5. Cruz, Ana F; Fonseca, Nuno A; Moura, Vera; Simões, Sérgio; Moreira, JN. "Enhanced efficacy of targeted synergistic drug combinations against nucleolin-overexpressing ovarian cancer cell lines.". Trabalho apresentado em XIII CNC Annual Meeting, 2015.
Resumo em conferência
  1. Chiara, Brignole; Bensa, Veronica; Zotto, Genny Del; Bruno, Silvia; Fonseca, Nuno A; Cruz, Ana F; Paolo, Daniela Di; et al. "Abstract A101: Nucleolin: A novel cell surface protein for neuroblastoma targeted therapy". Trabalho apresentado em AACR-NCI-EORTC International conference on Molecular Targets and Cancer Therapeutics, 2019.
    10.1158/1535-7163.targ-19-a101
  2. Cruz, Ana F.; Fonseca, Nuno A.; Gonçalves, Nélio; Moura, Vera; Simões, Sérgio; Moreira, João Nuno. "Abstract 3622: Differential effect of liposomal C6-ceramide/doxorubicin targeted to nucleolin and conventional combinations against triple negative breast cancer stem cells". Trabalho apresentado em American Association for Cancer Research Annual Meeting 2019, 2019.
    10.1158/1538-7445.am2019-3622
  3. Cruz, Ana Filipa; Fonseca, Nuno André; Sampaio, Susana F.; Moura, Vera; Almeida, Ramiro D.; Simões, Sérgio; Moreira, João Nuno. "Abstract 2194: Synergistic cytotoxicity of targeted liposomes containing doxorubicin and C6-ceramide against nucleolin-overexpressing ovarian cancer cells is supported by the downregulation of the Akt pathway". Trabalho apresentado em American Association for Cancer Research Annual Meeting 2017, 2017.
    10.1158/1538-7445.am2017-2194

Propriedade Intelectual

Patente
  1. Cruz, Ana F; Moura, V; Fonseca N; Simões, S; Moreira, JN. 2020. "Overcoming drug resistance associated with cancer stem cells and methods thereof". Portugal.
Atividades

Apresentação oral de trabalho

Título da apresentação Nome do evento
Anfitrião (Local do evento)
2022/04/13 Differential effect of F3 peptide-targeted liposomes containing doxorubicin and ceramides and non-targeted drug combinations against nucleolin-overexpressing cancer cell lines. Advanced Therapies Course/Doctoral Program in Experimental Biology and Biomedicine (PDBEB)
Center for Neuroscience and Cell Biology/University of Coimbra (Coimbra, Portugal)
2022/01/08 The impact of different liposomal formulations on nucleolin-overexpressing cancer cell lines Módulo III:Nanotecnologias/Mestrado em Biotecnologia Farmacêutica
Faculty of Pharmacy/University of Coimbra (Portugal)
2021/04/28 Differential effect of targeted and non-targeted drug combinations against nucleolin-overexpressing cell lines. Curricular unit: Nanomedicamentos/Mestrado Integrado em Ciências Farmacêuticas
Faculty of Pharmacy, University of Lisbon
2021/04/22 Differential effect of F3 peptide-targeted liposomes containing doxorubicin and C6-ceramide and non-targeted drug combinations against nucleolin-overexpressing cancer cell lines. Advanced Therapies Course/Doctoral Program in Experimental Biology and Biomedicine (PDBEB)
Center for Neuroscience and Cell Biology/University of Coimbra (Coimbra, Portugal)
2020/11/17 Differential effect of targeted and non-targeted drug combinations against nucleolin-overexpressing cell lines Mestrado em Investigação Biomédica (MIB)
Faculty of Medicine, University of Coimbra (Coimbra, Portugal)
2019/11/15 Synergistic cytotoxicity of targeted liposomal C6-ceramide and doxorubicin against nucleolin-overexpressing cancer cells is supported by the downregulation of the PI3K/Akt pathway. 1st Annual Meeting in Pharmaceutical Sciences
Faculty of Pharmacy, University of Coimbra (Coimbra, Portugal)
2019/03/27 A new perspective about anti-cancer therapies. Project "Cientificamente Provável" established between "Centro de Inovação em Biomedicina e Biotecnologia da Universidade de Coimbra" and "Bibliotecas Escolares de Mira"
Escola Secundária com 3.ºCEB Dr. a Maria Cândida (Coimbra, Portugal)
2017/04/23 The enhanced efficacy of targeted liposomes containing doxorubicin and C6-ceramide against nucleolin-overexpressing cancer cell lines is supported by the downregulation of the Akt pathway. 1st SPLC-CRS Young Scientist Meeting
Spanish Portuguese Local Chapter of the Controlled Release Society (Santiago de Compostela, Espanha)

Organização de evento

Nome do evento
Tipo de evento (Tipo de participação) 		Instituição / Organização
2017/11/01 - 2018/01/16 As a member of the Young section of the SPLC-CRS, I contributed in the whole process of organization of the XII Spanish-Portuguese Conference on Controlled Drug Delivery: Tailoring drug delivery systems to the patients' needs. For example, I participated in the selection of venue and catering, organization of the poster area and carring microphones during discussion. (2018/01/14 - 2018/01/16)
Conferência (Membro da Comissão Organizadora)
 Universidade de Coimbra, Portugal

Participação em evento

Descrição da atividade
Tipo de evento 		Nome do evento
Instituição / Organização
2021/10/14 - 2021/10/14 O FIC.A foi pensado para inovar, romper estaticismos e fundar uma nova realidade que cativasse quem, por algum motivo, se encontra afastado do mundo da ciência e da tecnologia. Uma verdadeira celebração da ciência em todas as suas vertentes, um festival de conhecimento, uma oportunidade para aprender, trocar experiências, estabelecer laços e inspirar públicos de todas as idades. https://www.fica.pt/
Festival
 Festival Internacional de Ciência, FICA 2021
Camara Municipal Oeiras, Portugal

Senciência, Portugal
2019/09/27 - 2019/09/27 European Researchers' Nights are public events dedicated to bringing researchers closer to the public. They showcase the diversity of research and highlight the impact of research on our daily lives. The aim is also to motivate young people to embark on research careers. The events promote how researchers contribute to our society by displaying their work in an interactive and engaging forum. https://ec.europa.eu/research/mariecurieactions/actions/european-researchers-night_en
Outro
 European Researchers' Night
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal
2019/03/01 - 2019/03/29 Brain Awareness Week (BAW) is a global campaign to increase public awareness of the progress and benefits of brain research promoted internationally by Federation of European Neuroscience Societies (FENS) and DANA Foundation and nationally by Ciência Viva and Sociedade Portuguesa de Neurociências. dana.org/BAW
Outro
 Brain Awareness Week
Universidade de Coimbra Centro de Neurociências e Biologia Celular, Portugal

Membro de associação

Nome da associação Tipo de participação
2015 - Atual Young Section of the Spanish-Portuguese Local Chapter of the Controlled Release Society
2012/07 - Atual Portuguese Order of Pharmacists (OF)